Saratin for inhibiting platelet adhesion to collagen

Details Saratin for inhibiting platelet adhesion to collagen Saratin for inhibiting platelet adhesion to collagen

2005-04-19

2005-04-19

Weber, Jon (Department: 1653)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S350000, C424S094640

Reexamination Certificate

active

06881722

ABSTRACT:
Use of the polypeptide Saratin for the manufacture of a medicament having the capability to significantly decrease platelet adhesion and platelet accumulation after vascular injuries or endarterectomy. The invention furthermore relates to a novel medical use of Saratin as an inhibitor of thrombosis and intimal hyperplasia, wherein the Saratin polypeptide may be used locally as a topical agent or as a coating on, or otherwise incorporated or associated with medical devices.

REFERENCES:
patent: 4898734 (1990-02-01), Mathiowitz et al.
patent: 5246715 (1993-09-01), Eldor et al.
patent: 5616608 (1997-04-01), Kinsella et al.
patent: WO 9207005 (1992-04-01), None
patent: WO 9501375 (1995-01-01), None
patent: WO 0056885 (2000-09-01), None
Barnes CS et al., “Production and characterization of saratin, an inhibitor of von Willebrand factor-dependent platelet adhesion to collagen,” Seminars in Thrombosis and Hemostasis, vol. 27, No. 4, pp. 337-348, Aug. 2001.

Affiliated with

Also associated with

Rating

Saratin for inhibiting platelet adhesion to collagen does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Saratin for inhibiting platelet adhesion to collagen, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Saratin for inhibiting platelet adhesion to collagen will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3421139